This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by de Groot, J. W. B. Articles by Voest, E. E. Search for Related Content PubMed PubMed Citation Articles by de Groot, J. W. B. Articles by Voest, E. E. Related Collections Thyroid Endocrine Oncology

A Phase II Trial of Imatinib Therapy for Metastatic Medullary Thyroid Carcinoma

Department of Endocrinology (J.W.B.d.G., M.M.d.V., T.P.L.), University Medical Center Groningen, University of Groningen, 9700 AB Groningen, The Netherlands; Departments of Medical Oncology (B.A.Z., E.E.V.) and Endocrinology (C.J.M.L.), University Medical Center Utrecht, 3508 GA Utrecht, The Netherlands; and Department of Medical Oncology (P.Q.v.U.-M.), Gosford Hospital, Gosford, New South Wales 2250, Australia

Address all correspondence and requests for reprints to: B. A. Zonnenberg, M.D., Ph.D., Department of Medical Oncology, University Medical Center Utrecht, P.O. Box 85500, 3508 GA Utrecht, The Netherlands. E-mail: b.zonnenberg{at}umcutrecht.nl.

Context: Medullary thyroid carcinoma (MTC) metastasizes early in its clinical course. No effective systemic therapy is available. Generally (somatic or germline), mutations in the rearranged during transfection gene are considered essential in the pathogenesis of MTC.

Objective: We investigated imatinib, a tyrosine kinase inhibitor, as a potential treatment in patients with disseminated MTC.

Design: A phase II study was initiated using 600 mg imatinib daily with a possible dose increase to 800 mg in case of progression. Standard Response Evaluation Criteria in Solid Tumors were used using computed tomography or magnetic resonance imaging every 2 months.

Results: There were 15 patients with disseminated MTC treated for up to 12 months. No objective responses were observed. Four patients had stable disease over 24 months. Three patients stopped treatment due to toxic effects [fatigue (n = 2) and nausea (n = 1)]. In four cases the dose of imatinib was decreased because of toxicity [rash and malaise (n = 2) and laryngeal swelling (n = 2)]. Emergency tracheotomy was performed in two cases due to mucosal swelling of the larynx in patients with recurrent nerve palsy and a narrow vocal cleft. In nine patients with a history of a thyroidectomy, the dose of supplemental thyroid hormone was increased because of serious hypothyroidism.

Conclusions: Imatinib therapy yielded no objective responses and induced considerable toxicity in patients with MTC. A minority of patients had stable disease. Patients with supplemented hypothyroidism or with recurrent nerve palsy are specifically at risk for serious adverse events and need special attention when treated with imatinib.

This article has been cited by other articles:

				A. M. Tsimberidou, C. Vaklavas, S. Wen, D. Hong, J. Wheler, C. Ng, A. Naing, S. Tse, N. Busaidy, M. Markman, et al. Phase I Clinical Trials in 56 Patients with Thyroid Cancer: The M. D. Anderson Cancer Center Experience J. Clin. Endocrinol. Metab., November 1, 2009; 94(11): 4423 - 4432. [Abstract] [Full Text] [PDF]

				J. A Woyach and M. H Shah New therapeutic advances in the management of progressive thyroid cancer Endocr. Relat. Cancer, September 1, 2009; 16(3): 715 - 731. [Abstract] [Full Text] [PDF]

				M. J. Schlumberger, R. Elisei, L. Bastholt, L. J. Wirth, R. G. Martins, L. D. Locati, B. Jarzab, F. Pacini, C. Daumerie, J.-P. Droz, et al. Phase II Study of Safety and Efficacy of Motesanib in Patients With Progressive or Symptomatic, Advanced or Metastatic Medullary Thyroid Cancer J. Clin. Oncol., August 10, 2009; 27(23): 3794 - 3801. [Abstract] [Full Text] [PDF]

				S. I. Sherman Advances in Chemotherapy of Differentiated Epithelial and Medullary Thyroid Cancers J. Clin. Endocrinol. Metab., May 1, 2009; 94(5): 1493 - 1499. [Abstract] [Full Text] [PDF]

				F. Illouz, S. Laboureau-Soares, S. Dubois, V. Rohmer, and P. Rodien Tyrosine kinase inhibitors and modifications of thyroid function tests: a review Eur. J. Endocrinol., March 1, 2009; 160(3): 331 - 336. [Abstract] [Full Text] [PDF]

				S. I. Sherman, L. J. Wirth, J.-P. Droz, M. Hofmann, L. Bastholt, R. G. Martins, L. Licitra, M. J. Eschenberg, Y.-N. Sun, T. Juan, et al. Motesanib Diphosphate in Progressive Differentiated Thyroid Cancer N. Engl. J. Med., July 3, 2008; 359(1): 31 - 42. [Abstract] [Full Text] [PDF]

				R. S. Sippel, M. Kunnimalaiyaan, and H. Chen Current Management of Medullary Thyroid Cancer Oncologist, May 1, 2008; 13(5): 539 - 547. [Abstract] [Full Text] [PDF]